Aspen to sell European thrombosis business for €641.9m

  • 📰 BDliveSA
  • ⏱ Reading Time:
  • 36 sec. here
  • 2 min. at publisher
  • 📊 Quality Score:
  • News: 18%
  • Publisher: 63%

Malaysia News News

The proceeds of the sale to US pharmaceutical group Mylan will be used to reduce debt, Aspen says

Africa’s largest drugmaker Aspen Phamacare has agreed to sell its European thrombosis business to US group Mylan for €641.9m .

The proceeds of the sale of business, which focuses on anticoagulant drugs, will be used to pay down debt, Aspen said.Aspen had R33.4bn in net debt at the end of December, and said in March that it was reviewing its businesses in Europe. Aspen said on Tuesday the sale of the European thrombosis business supports its strategy of continuing to reshape the group towards a greater concentration of revenue in emerging markets.

In morning trade on Tuesday, Aspen’s share had jumped 8.91% to R146, putting it on track for its best one-day performance in about two weeks. The group’s share has risen 22.5% so far in 2020, giving the group a market capitalisation of R66.6bn on Tuesday morning.

 

Thank you for your comment. Your comment will be published after being reviewed.
Please try again later.
We have summarized this news so that you can read it quickly. If you are interested in the news, you can read the full text here. Read more:

 /  🏆 12. in MY

Malaysia Malaysia Latest News, Malaysia Malaysia Headlines

Similar News:You can also read news stories similar to this one that we have collected from other news sources.

Third Chinese company has ‘fat finger’ issue, but analyst cries wolfShenzhen Changfang Group said shareholder accidentally sold 16,000 shares by imputing wrong ticker
Source: BDliveSA - 🏆 12. / 63 Read more »

Third Chinese company has ‘fat finger’ issue, but analyst cries wolfShenzhen Changfang Group said shareholder accidentally sold 16,000 shares by imputing wrong ticker
Source: BDliveSA - 🏆 12. / 63 Read more »